Impact of severity, duration, and etiology of hyperthyroidism on bone turnover markers and bone mineral density in men

BMC Endocrine Disorders

Volumn 11, Issue , 2011, Pages

  El Hadidy, El Hadidy M ^a   Ghonaim, Mohamed ^a   El Gawad, Soma S A ^a   El Atta, Mohamed A ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

Bon resorption markers; Bone formation markers; Bone mineral density; Hyperthyroidism; Osteoporosis

Indexed keywords

ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; CREATININE; DEOXYPYRIDINOLINE; OSTEOCALCIN;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE DENSITY; BONE TURNOVER; CALCIUM URINE LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE URINE LEVEL; DISEASE DURATION; DISEASE SEVERITY; DUAL ENERGY X RAY ABSORPTIOMETRY; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; LIOTHYRONINE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; OSTEOPOROSIS; PROTEIN BLOOD LEVEL; RADIUS; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TOXIC GOITER; URINE LEVEL;

EID: 79961114007     PISSN: None     EISSN: 14726823     Source Type: Journal    
DOI: 10.1186/1472-6823-11-15     Document Type: Article

References (34)

1. Allain TJ, McGregor AM. Thyroid hormones and bone. J Endocrinol 1993, 139:9-18. 10.1677/joe.0.1390009, 8254298.
2. Akalin A, Colak O, Alatas O, Efe B. Bone remodeling markers and serum cytokines in patients with hyperthyroidism. Clin Endocrinol 2002, 57(1):125-129.
3. Udayakumar N, Chandrasekaran M, Rasheed MH, Suresh RV, Sivaprakash S. Evaluation of bone mineral density in thyrotoxicosis. Singapore Med J 2006, 47(11):947-950.
4. Van de ven AC, Erdtsieck RJ. Changes of bone mineral density, quantitative ultrasound parameters and markers of bone turnover during treatment of hyperthyroidism. The Netherlands J Medicine 2008, 66(10):428-432.
5. Vestergaard P, Mosekilde L. Hyperthyroidism, bone mineral, and fracture risk-a meta-analysis. Thyroid 2003, 13(6):585-593. 10.1089/105072503322238854, 12930603.
6. Campos-Pastor MM, Munoz-Torres M, Escobar-Jimenez F, et al. Bone mass in females with different thyroid disorders: influence of menopausal status. Bone and Mineral 1993, 21:1-8. 10.1016/S0169-6009(08)80115-8, 8324416.
7. Jodar E, Munoz-Torres M, Escobar-Jimenez F, et al. Bone loss in hyperthyroid patients and in former hyperthyroid patients controlled on medical therapy: influence of etiology and menopause. J Clin Endocrinol 1997, 47:279-285.
8. Greenspan SL, Greenspan FS. The effect of thyroid hormone on skeletal integrity. Ann Intern Med 1999, 130(9):750-758.
9. Barsal G, Taneli F, Atay A, Hekimsoy Z, Erciyas F. Serum osteocalcin levels in hyperthyroidism before and after antithyroid therapy. Tohoku J Exp Med 2004, 203(3):183-188. 10.1620/tjem.203.183, 15240927.
10. Kraenzlin ME, Seibel M. Measurement of biochemical markers of bone resorption. Dynamics in bone and cartilage metabolism 2006, 541-564. Academic Press, Seibel M, Robins S, Bilezikian J.
11. Al-Shoumer KAS, Vasanthy BA, Al-Zaid MM. Effects of treatment of hyperthyroidism on glucose homeostasis, insulin secretion and markers of bone turnover. Endocr Pract 2006, 12(2):121-130.
12. Naylor KE, Eastell R. Measurement of biochemical markers of bone formation. Dynamics of bone and cartilage metabolism 2006, 529-540. Academic Press, Seibel M, Robins S, Bilezikian J.
13. Kraenzlin ME, Kraenzlin CA, Meier C, Giunta C, Steinmann B. Automated HPLC assay for urinary collagen cross-links: effect of age, menopause, and metabolic bone diseases. Clin Chem 2008, 54:1546-1553. 10.1373/clinchem.2008.105262, 18653826.
14. Kisakol G, Kaya A, Gonen S, Tunc R. Bone and calcium metabolism in subclinical autoimmune hyperthyroidism and hypothyroidism. Endocr J 2003, 50(6):657-661. 10.1507/endocrj.50.657, 14709834.
15. Endres DB, Rude RK. Mineral and bone metabolism. Tietz fundamentals of clinical chemistry 1996, 685-703. Philadelphia: WB Saunders, Burtis CA, Ashwood ER, 4.
16. Tietz NW, Shuey DF. Reference intervals for alkaline phosphatase. Activity determined by the IFCC and AACC reference methods. Clin Chem 1986, 32:1593-1594.
17. Garnero P, Delmas PD. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 1993, 77:1046-1053. 10.1210/jc.77.4.1046, 8104954.
18. Ladenson PW. Optimal laboratory testing for diagnosis and monitoring of thyroid nodules, goiter and thyroid cancer. Clin Chem 1996, 42:1183-1187.
19. Power MJ, Fottrell PF. Osteocalcin: diagnostic methods and clinical applications. Crit Rev Clin Lab Sci 1991, 28(4):287-335. 10.3109/10408369109106867, 1930680.
20. Saetung S, Chailurkit LO, Ongphiphadhanakul B. Acute changes in biochemical markers of bone resorption and formation after Thai traditional massage. J Med Assoc Thai 2010, 93(7):771-775.
21. Reid IR, Davidson JS, Wattie D, Wu F, Lucas J, Gamble GD, Rutland MD, Cundy T. Comparative responses of bone turnover markers to bisphosphonate therapy in paget's disease of bone. J Intern Bone and Miner Soci 2004, 35(1):224-230.
22. Wexler JA, Sharretts J. Thyroid and bone. Endocrinol Metab Clin North Am 2007, 36(3):673-705. 10.1016/j.ecl.2007.04.005, 17673124.
23. Galliford TM, Murphy E, Williams AJ, Bassett JH, Williams GR. Effects of thyroid status on bone metabolism: a primary role for thyroid stimulating hormone or thyroid hormone?. Minerva Endocrinol 2005, 30(4):237-246.
24. Gogakos AI, Bassett JHD, Williams GR. Thyroid and bone. Arch Biochem Biophys 2010, 503(1):129-136. 10.1016/j.abb.2010.06.021, 20599658.
25. Rosario PW. Bone and heart abnormalities of subclinical hyperthyroidism in women below the age of 65 years. Arq Bras Endocrinol Metab 2008, 52(9):1448-1451.
26. Williams GR. Actions of thyroid hormones in bone. Endokrynol Pol 2009, 60(5):380-388.
27. Bassett JHD, Williams GR. The molecular actions of thyroid hormones in bone. Trends Endocrinol Metab 2003, 14(8):356-364. 10.1016/S1043-2760(03)00144-9, 14516933.
28. Abe E, Marians RC, Yu W, et al. TSH is a negative regulator of skeletal remodeling. Cell 2003, 115(2):151-162. 10.1016/S0092-8674(03)00771-2, 14567913.
29. Heijckmann AC, Huijberts MSP, Geusens P, Vries J, Menheere P, Wolffenbuttel B. Hip bone mineral density, bone turnover and risk of fracture in patients on long-term suppressive L-thyroxine therapy for differentiated thyroid carcinoma. European J Endocrinol 2005, 153(1):23-29.
30. Lee MS, Kim SY, Lee MC, et al. Negative correlation between the changes in bone mineral density and serum osteocalcin in patients with hyperthyroidism. J Clin Endocrinol Metab 1990, 70:766-770. 10.1210/jcem-70-3-766, 2307730.
31. Nekrasova MR, Suplotova LA, Davydova LI. Features of osteopenic syndrome in diffuse toxic goiter. Ter Arkh 2005, 77(10):29-33.
32. Diamond T, Vine J, Smart R, et al. Thyrotoxic bone disease in women. A potentially reversible disorder. Ann Inter Med 1994, 120(1):8-11.
33. Marcocci C, Golia F, Bruno-Bossio G, et al. Carefully monitored levothyroxin suppressive therapy is not associated with bone loss in premenopausal women. J Clin Endocrinol Metab 1994, 78:818-823. 10.1210/jc.78.4.818, 8157704.
34. Belaya ZE, Melnichenko GA, Rozhinskaya LY, Fadeev VV, et al. Subclinical hyperthyroidism of variable etiology and its influence on bone in postmenopausal women. Hormones 2007, 6(1):62-70.